联合检测食管鳞癌放疗前后血清SCC,VEGF、CYFRA21-1的临床意义

摘要

Objective:To evaluate whether the detection of SCC combined with VEGF and CYFRA21-1 in e-sophageal squamous cell carcinoma patients treated by radiotherapy would reflect the prognosis of esophagus carcinoma. Methods: Serum SCC, VEGF and CYFRA21-1 were determined by enzyme linked immunosorbent assay (ELBA) and (or) Electrical cherniluminescent immunoassay (ECIiA)in 80 patients with esophageal squamous cell carcinoma treated by radiation therapy ( RT group) and in 20 healthy controls. Results: The concentrations of serum SCC, VEGF and CYFRA21 -1 were significantly higher in the trial group than those in the control group(P<0.05). In the trial group,the concentrations of SCC, VEGF and CYFRA21-1 at each stage during radiotherapy were significantly lower than those before radiotherapy (P < 0.05). Conclusion: Combined detection of SCC, VEGF and CY-FRA21 -1 is helpful to prognosis evaluation of esophageal squamous cell carcinoma patient treated by radiation therapy.%目的:探讨联合检测食管鳞癌患者血清鳞状上皮细胞癌相关抗原(SCC)、血管内皮生长因子(VEGF)、细胞角化素蛋白片段19( CYFRA21-1)对放疗效果评估的价值.方法:采用酶联免疫吸附法( ELISA)或电化学发光免疫分析法(ECLIA)测定80例食管鳞癌患者放疗前、后血清SCC、VEGF、CYFRA21-1水平,并以20例健康者为对照.结果:食管鳞癌组血清SCC、VEGF、CYFRA21-1水平明显高于对照组,食管鳞癌组血清SCC、VEGF、CYFRA21-1对放疗后有效者(CR+ PR)均明显低于放疗前(P＜0.05).结论:血清SCC、VEGF、CYFRA21-1联合检测食管鳞癌放疗疗效和预后判断有较好的临床应用价值.